Breast Cancer Trials
The Australian and New Zealand breast cancer trials group, a Breast International Group partner in SOFT/TEXT, APHINITY, OlympiA and POSITIVE.
Founded in 1978 as the ANZ Breast Cancer Trials Group and renamed Breast Cancer Trials, it is one of the longest-running academic breast cancer groups and a founding member of the Breast International Group. It co-led the IBCSG SOFT and TEXT trials of ovarian suppression, contributed to APHINITY, OlympiA and the POSITIVE pregnancy-interruption study, and runs its own trials such as EXPERT (omitting radiotherapy in low-genomic-risk luminal A disease) and DECRESCENDO. A large consumer advisory panel shapes protocol design. Trials are coordinated from Newcastle with sites across Australia and New Zealand.
- SOFT / TEXT (with IBCSG)
- OlympiA and APHINITY (with BIG)
- EXPERT (radiotherapy omission)
- POSITIVE (pregnancy after endocrine therapy)
Pages like this
not linked directly; found by shared links- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares OlympiA, PARP inhibitors, Olaparib, Triple-negative breast cancer (TNBC).
- InstitutionInstitut Jules Bordet
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), Trastuzumab, HER2-positive breast cancer.
- InstitutionBreast Cancer Research Foundation
Shares Sherene Loi, Peter MacCallum Cancer Centre, PARP inhibitors, HER2-positive breast cancer.
- PersonDavid Cameron
Shares APHINITY, Breast International Group (BIG), HER2-positive breast cancer.
- InstitutionSOLTI Cancer Research Group
Shares Breast International Group (BIG), Trastuzumab, HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- InstitutionGuy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre
Shares OlympiA, PARP inhibitors, Olaparib, Triple-negative breast cancer (TNBC).
- InstitutionGEICAM Spanish Breast Cancer Group
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- ProductGoserelin / leuprolide (ovarian function suppression)
Shares SOFT & TEXT, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.